Company intelligence / Profile preview

ViroVax

Lawrence, Kansas, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

ViroVax's adjuvant Alhydroxiquim-II has been licensed and incorporated into Bharat Biotech’s COVAXIN vaccine, which achieved high efficacy in COVID-19 prevention in India; the company has R&D programs for vaccines and adjuvants targeting multiple emerging infectious diseases, primarily in pre-clinical stages[3][4][5][6].

Therapeutic areas: Infectious Diseases
Modalities: VaccineAdjuvantSmall molecule
Industry: Biotech

Partnerships

Bharat Biotech[3][5][6][7]

Beyond the preview

Go deeper on ViroVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroVax.

Explore the full profile